In this issue:
Rituximab, abatacept or tocilizumab in RA after inadequate anti-TNF response
6 weeks of prednisolone for hand OA
Costs associated with AxSpA in NZ
Disease-modifying effects of a novel cathepsin K inhibitor in OA
Naproxen vs. low-dose colchicine for gout flares in primary care
Predictors of response to conventional synthetic DMARDs in early seronegative RA
Disease activity and radiographic damage in early RA with treat-to-target therapy
CV safety of tocilizumab vs. etanercept in RA
Combinations of DMARDs and glucocorticoid bridging in early RA
Upadacitinib in active ankylosing spondylitis
Please login below to download this issue (PDF)